fluvoxamine - versus control - for COVID-19 pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

clinical deterioration 0.07 [0.00, 1.26]< 10%1 study (1/-)96.3 %some concernnot evaluable moderateimportant-

safety endpoints 00

serious adverse events 0.17 [0.02, 1.49]< 10%1 study (1/-)94.4 %some concernnot evaluable moderateimportant-
adverse events 0.98 [0.40, 2.38]< 10%1 study (1/-)51.9 %some concernnot evaluable moderatenon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.